405 related articles for article (PubMed ID: 25833790)
21. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
22. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
23. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
25. Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
J Comput Assist Tomogr; 2015; 39(5):810-5. PubMed ID: 26035406
[TBL] [Abstract][Full Text] [Related]
26. Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL.
Song MK; Chung JS; Kim SJ; Kim SS; Shin HJ
Ann Hematol; 2015 Jun; 94(6):995-1001. PubMed ID: 25687840
[TBL] [Abstract][Full Text] [Related]
27. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
28.
Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
[TBL] [Abstract][Full Text] [Related]
29. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
30. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
31. [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
Zhang Y; Fan Y; Yang Z; Ying Z; Song Y; Zhu J; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):824-9. PubMed ID: 26477759
[TBL] [Abstract][Full Text] [Related]
32. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
33. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
34. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
Nagle SJ; Chong EA; Chekol S; Shah NN; Nasta SD; Glatstein E; Plastaras JP; Torigian DA; Schuster SJ; Svoboda J
Cancer Med; 2015 Jan; 4(1):7-15. PubMed ID: 25205600
[TBL] [Abstract][Full Text] [Related]
35. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
[TBL] [Abstract][Full Text] [Related]
36. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
[TBL] [Abstract][Full Text] [Related]
37. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
38. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
Kim J; Song YS; Lee JS; Lee WW; Kim SE
Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
[TBL] [Abstract][Full Text] [Related]
39. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
